Ardelyx, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone Q4 filing; selected fourth-quarter results are included below. Amounts are in U.S. dollars.
Business context
Ardelyx is a biopharmaceutical company focused on kidney and cardiorenal diseases. It had no product-sales revenue in 2020; revenue came from collaboration, licensing, and product-supply arrangements. Its lead candidate, tenapanor, was under FDA review for controlling serum phosphorus in dialysis patients with chronic kidney disease (CKD). The FDA accepted the NDA in September 2020 and set an April 29, 2021 PDUFA date. Tenapanor was already FDA-approved as IBSRELA for adult IBS-C, but Ardelyx had not launched it itself in the United States. RDX013 was in Phase 2 development for hyperkalemia; RDX020 remained a discovery program for metabolic acidosis.
Key financial metrics
| Metric | FY2020 | FY2019 |
|---|---|---|
| Total revenue | $7.6 million | $5.3 million |
| Research and development expense | $65.1 million | $71.7 million |
| General and administrative expense | $33.2 million | $24.3 million |
| Operating loss | $90.8 million | $91.3 million |
| Net loss | $94.3 million | $94.9 million |
| Net loss per share, basic and diluted | $1.05 | $1.47 |
| Cash, cash equivalents and investments at year-end | $188.6 million | $247.5 million |
| Net cash used in operating activities | $81.4 million | $76.5 million |
| Loan payable, current and non-current | $50.8 million | $50.0 million |
2020 revenue comprised $5.4 million collaborative development revenue, $1.5 million product-supply revenue, and $0.7 million licensing revenue. Revenue was entirely from collaborations; no product-sales revenue or meaningful commercial-product margin was reported. Year-end current assets were $194.7 million and current liabilities were $28.4 million. The company said available cash and investments were expected to fund planned expenditures and obligations for at least 12 months from the March 8, 2021 financial-statement issuance date; this estimate depended on assumptions and could change.
Fourth-quarter 2020 revenue was $1.8 million, operating expenses were $29.5 million, and net loss was $28.9 million, compared with revenue of $2.3 million, operating expenses of $21.1 million, and net loss of $19.8 million in Q4 2019.
Changes versus prior year
- Revenue rose 43% year over year, mainly from recognition of the KKC research collaboration, higher tenapanor supply sales to KKC, and a Knight development milestone. The prior-year comparison included a $3.0 million Fosun milestone that did not recur.
- R&D expense declined 9%, primarily as Phase 3 tenapanor studies wound down; this was partly offset by KKC research and NDA filing costs.
- G&A expense increased 37% as the company staffed and prepared commercial infrastructure for a potential U.S. tenapanor launch.
- Net loss was nearly flat, while loss per share narrowed to $1.05 from $1.47, partly reflecting a higher weighted-average share count following 2019 equity financings.
- Cash and investments fell $58.9 million. Operating cash use increased by $5.0 million; investing cash flow was affected by purchases of investments. 2020 financing included $21.0 million of net ATM proceeds, versus substantial public-offering and private-placement proceeds in 2019.
Outlook, risks and notable items
- Management expected substantial operating losses to continue, driven by tenapanor development and potential commercialization, RDX013 development, and research programs. No numeric revenue or earnings guidance was provided.
- Tenapanor’s phosphorus-control NDA was pending at year-end. Approval, label, launch timing, market acceptance, pricing, coverage, reimbursement, and the ability to build a sales organization remained uncertain. Management planned to commercialize the indication in the United States itself if approved.
- Management highlighted the possible inclusion, beginning in 2025 absent further changes, of oral ESRD-related drugs without injectable or intravenous equivalents in the Medicare dialysis bundle, potentially affecting reimbursement and economics.
- Tenapanor’s principal reported adverse event in Phase 3 trials was diarrhea: 52% in PHREEDOM and 39% in BLOCK, generally mild to moderate. Manufacturing depends on third parties, and supply, quality, or regulatory problems could delay development or commercialization.
- The $50 million term loan matures November 1, 2022, bears interest at one-month LIBOR plus 7.45%, and is secured by substantially all assets other than intellectual property. Interest-only payments were extended through December 1, 2021, subject to loan terms; scheduled principal repayment could start earlier if FDA approval was not obtained by May 31, 2021 or a complete response letter was issued. The company reported covenant compliance at year-end.
- After year-end, Ardelyx sold 4.9 million additional shares under its ATM program from January 2 through February 28, 2021, for $35.0 million gross proceeds. This strengthened liquidity but diluted shareholders.
- COVID-19 had not materially adversely affected 2020 operations, according to the filing, but could disrupt clinical trials, manufacturing, hiring, and launch preparation. The filing reported no material pending litigation and no accrued contingent liabilities at year-end.
- A prior-period clinical-trial accrual error led to a $3.6 million reduction in 2019 R&D expense. Management said the error was not material to full-year 2018 or 2019 results; the related material weakness in internal control was reported remediated as of December 31, 2019.
Important facts for investors to verify
- FDA action, final labeling, and launch readiness for tenapanor’s phosphorus-control indication, including the effect of any review delay or additional FDA requirements.
- Actual cash burn, financing needs, and dilution, including post-year-end ATM share sales and the timing of loan principal payments.
- Reimbursement arrangements and the potential effect of the ESRD payment bundle on tenapanor’s price, access, and profitability.
- Commercial supply capacity and manufacturing compliance, given Ardelyx’s reliance on contract manufacturers.
- Whether tenapanor’s tolerability, particularly diarrhea incidence, and RDX013’s clinical results support durable adoption and development progress.